Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTAR study of amivantamab combinations in EGFR-mutant advanced non-small cell lung cancer
KCT0011151Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, lazertinib, pemetrexed, carboplatin in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
amivantamablazertinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0011151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011151.